Clinical trial
Comparison of Sequential IV/PO Moxifloxacin With IV Piperacillin/Tazobactam…
NCT00402727 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00402727 |
|---|---|
| Title | Comparison of Sequential IV/PO Moxifloxacin With IV Piperacillin/Tazobactam Followed by PO Amoxicillin/Clavulanic Acid in Patients With a Complicated Skin and Skin Structure Infection |
| Official title | A Prospective, Randomized, Double Dummy, Double Blind, Multinational, Multicenter Trial Comparing the Safety and Efficacy of Sequential (Intravenous/Oral) Moxifloxacin 400 mg OD to Intravenous Piperacillin/Tazobactam 4.0/0.5 g Every 8 Hours Followed by Oral Amoxicillin/Clavulanic Acid Tablets… |
| Lead sponsor | Bayer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Abscess, Wound Infection, Diabetic Foot, Ulcer |
| Intervention type | Drug |
| Interventions | Moxifloxacin (Avelox, BAY12-8039), Piperacillin/Tazobactam & Amoxicillin/Clavulanic acid |
| Enrollment | 813 |
| Start date | Sep 1, 2006 |
| Primary completion | Jun 1, 2008 |
| Completion | Jun 1, 2008 |
| First posted | Nov 22, 2006 |
| Last update posted | Nov 7, 2014 |
| Countries | Austria, Belgium, Bulgaria, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Latvia, Lithuania and 8 more |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: